OrbiMed’s Adamas Pharmaceuticals ADMS Stock Holding History

OrbiMed’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-100,000	Closed	-$1.3M	–	159
2018 Q3	$2M	Buy	+100,000	New	+$2.35M	0.02%	140

Other funds holding ADMS

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

OrbiMed's ADMS Position: Q4 2018 in Review

OrbiMed sold out of Adamas Pharmaceuticals (ADMS) in Q4 2018, closing a stake of 100,000 shares — an estimated $1.3M sold.

OrbiMed first reported a position in ADMS in Q3 2018 and held it in 1 quarter. The position peaked at $2M in Q3 2018. 98 funds tracked by Wall St. Rank hold ADMS as of Q4 2018.

OrbiMed reported no remaining Adamas Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
OrbiMed sold 100,000 Adamas Pharmaceuticals shares in Q4 2018, an estimated $1.3M.
OrbiMed first reported a position in Adamas Pharmaceuticals in Q3 2018 and held it in 1 quarter.
OrbiMed's Adamas Pharmaceuticals position peaked at $2M in Q3 2018.
98 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2018.

Based on OrbiMed's 13F filing for Q4 2018, filed 14 Feb 2019.